
John O'donnell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/240423/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nature Microbiology, 2017, 2, 17104.	13.3	187
2	Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of <i>Neisseria gonorrheae</i> , Including Multi-Drug-Resistant Isolates. ACS Infectious Diseases, 2020, 6, 1332-1345.	3.8	73
3	Rational design of a new antibiotic class for drug-resistant infections. Nature, 2021, 597, 698-702.	27.8	69
4	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases. Journal of Medicinal Chemistry, 2020, 63, 12511-12525.	6.4	44
5	Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	17
6	Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	15
7	Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282. ACS Infectious Diseases, 2020, 6, 1378-1388.	3.8	13
8	Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	11
9	A randomized, doubleâ€blind, placebo―and positiveâ€controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects. Clinical and Translational Science, 2021, 14, 1423-1430.	3.1	5
10	Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy Adults. Antimicrobial Agents and Chemotherapy, 2021, 65, e0129221.	3.2	5
11	Human Pharmacokinetics and Dose Projection of ETX2514/Sulbactam Combination for Use in the Treatment of Infections Caused by Acinetobacter baumannii. Open Forum Infectious Diseases, 2016, 3, .	0.9	1